Public health officials are closely monitoring an early adn potentially severe flu season in the Northern Hemisphere, driven by the increasing circulation of influenza A(H3N2) [[1]]. while the flu vaccine is expected to offer protection against serious illness, new data indicates the dominant strain, a subclade designated K, has undergone notable mutations [[2]], raising questions about vaccine effectiveness and the need for continued surveillance. The European centre for Disease prevention and Control is assessing the potential impact of these changes, as health systems prepare for a possible surge in cases.
Despite the anticipated rise of a new strain of influenza A(H3N2), the flu vaccine is expected to offer significant protection against severe illness and death this season. The European Centre for Disease Prevention and Control (ECDC) recently reported a moderate level of vaccine effectiveness in its latest assessment.
Health officials across the Northern Hemisphere are closely monitoring an unusually early start to the flu season, coupled with the increasing dominance of the A(H3N2) virus. This strain has been less prevalent in recent years, leading to a potential decrease in population immunity. Furthermore, the A(H3N2) virus has undergone significant changes since the current vaccine was developed, raising concerns about how well it will match circulating strains.
To continue reading, please sign in.
Dear readers,
this article is only visible to logged-in users.
Please log in or register for a new account.
With a free registration you benefit from the following advantages:
Get access to non-public content
Influenza season is starting earlier than usual in the Northern Hemisphere, and a specific strain is gaining prominence, prompting health agencies to assess the potential impact on vaccine effectiveness. Understanding how well the flu shot protects against circulating strains is crucial for public health planning and individual preventative measures.
The ECDC’s latest report highlights the increasing prevalence of influenza A(H3N2), a subtype that has played a less significant role in recent flu seasons. This reduced circulation means a larger portion of the population may have limited immunity to this particular strain. Adding to the concern, the A(H3N2) virus has mutated considerably since the composition of the current flu vaccine was determined.
Specifically, the dominant sub-clade, now known as K (previously designated J.2.4.1), exhibits several key differences from the virus used to create the vaccine (A/Croatia/10136RV/2023). These differences – including changes at positions K189R, T135K, N145S, N158D, and I160K – could potentially reduce the ability of antibodies generated by vaccination or prior infection to neutralize the virus. This mismatch raises the possibility that the vaccine may be less effective against this evolving strain.
Despite these challenges, the ECDC anticipates that the flu vaccine will still provide substantial protection against severe illness and hospitalization for many individuals. The findings could guide future vaccination strategies and emphasize the importance of staying informed about circulating strains.
